ArticleCancer discovery2022

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.

Guy Jerusalem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.